We are preparing the requested document. Please wait, this may take a while...!
|Antigen||V-Erb-B2 erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/glioblastoma Derived Oncogene Homolog (Avian) (ERBB2) Antibodies|
|Reactivity||Human, Mouse (Murine), Rat (Rattus) Alternatives|
|Conjugate||This HER2 antibody is un-conjugated Alternatives|
Enzyme Immunoassay (EIA), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
|Supplier||Log in to see|
Product Details anti-HER2 AntibodyTarget Details HER2 Application Details Handling Images
|Specificity||This antibody reacts to erbB-2.|
|Purification||Affinity chromatography purified via peptide column|
|Immunogen||erbB-2 antibody was raised against a 19 amino acid peptide near the carboxy terminus of human erbB-2.|
Target Details HER2Product Details anti-HER2 Antibody Application Details Handling Images back to top
|Alternative Name||CD340 / ERBB2 / HER2 (ERBB2 Antibody Abstract)|
|Background||The ErbB family consists of four closely related tyrosine kinase receptors that act as potent mediators of normal cell growth and development. Aberrant expression or function of one or more of these receptors can play a major role in the development and evolution of cancer. ErbB-2, also known as HER2, has been implicated in the evolution of both breast and gastric cancers, and is evident in other cancer types such as ovarian and salivary gland tumors. ErbB-2 possesses an active tyrosine kinase domain, but no direct ligand has been identified yet. ErbB-2 is the preferred binding partner to the other members of the ErbB family and is thought to act primarily through the Ras-MAPK, PI3k-PKB/Akt, and PLC-PKC signaling pathways. Numerous anti-cancer strategies have been employed against erbB-2, such as antibody-based therapies to prevent ligand binding or receptor activation through dimerization, antibody-dependent cell mediated cytotoxicity, in addition to direct kinase inhibition to prevent molecular activation/downstream signaling.Synonyms: HER-2, MNL19, NEU, NEU proto-oncogene, NGL, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, c-erbB-2, p185erbB2|
|Pathways||RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development|
Application DetailsProduct Details anti-HER2 Antibody Target Details HER2 Handling Images back to top
ELISA. Western Blot: 1 - 2 μg/mL. Immunohistochemistry.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
|Restrictions||For Research Use only|
HandlingProduct Details anti-HER2 Antibody Target Details HER2 Application Details Images back to top
|Buffer||PBS containing 0.02 % sodium azide.|
|Precaution of Use||This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage Comment||Store the antibody undiluted at 2-8 °C.|